替代供者骨髓移植联合移植后环磷酰胺作为获得性重型再生障碍性贫血初始治疗
这项前瞻性2期试验评估了减低强度预处理HLA单倍体相合骨髓移植联合移植后环磷酰胺为基础的移植物抗宿主病预防方案,作为重型再生障碍性贫血患者的初始治疗。患者中位年龄25岁,中位随访40.9个月,27例患者1、2、3年总生存率均为92%(95%CI,83-100)。接受400 cGy全身照射的20例连续患者总生存率达100%,且移植物抗宿主病发生率低。
要点
- 27例重型再生障碍性贫血患者接受HLA单倍体相合骨髓移植联合移植后环磷酰胺方案,1、2、3年总生存率均为92%(95%CI,83-100)。
- 第100天2级或4级急性移植物抗宿主病累积发生率为7%(95%CI,不适用-17),2年慢性移植物抗宿主病累积发生率为4%(95%CI,不适用-11)。
- 前7例接受较低剂量全身照射(200 vs 400 cGy)的患者移植物失败更常见(7例中3例 vs 较高剂量组20例中0例,P=.01,Fisher精确检验)。
核心结论
- HLA单倍体相合骨髓移植联合移植后环磷酰胺、采用400 cGy全身照射,在20例连续患者中实现100%总生存且移植物抗宿主病发生率低。
- 该方案不仅避免了免疫抑制治疗的不良后果及其较低的无失败生存率,使用单倍体相合供者还扩大了所有人群中骨髓移植的可及性。
研究设计与样本
- 前瞻性2期试验,评估减低强度预处理HLA单倍体相合骨髓移植联合移植后环磷酰胺为基础的移植物抗宿主病预防方案,作为重型再生障碍性贫血患者的初始治疗。
- 患者中位年龄25岁(范围,3-63岁),中位随访时间40.9个月(95%CI,29.4-55.7),超过35%的入组患者来自代表性不足的种族/族裔群体。
- 临床试验注册号为NCT02833805。
主要发现
- 第100天2级或4级急性移植物抗宿主病累积发生率为7%(95%CI,不适用-17),2年慢性移植物抗宿主病累积发生率为4%(95%CI,不适用-11)。
- 27例患者1、2、3年总生存率均为92%(95%CI,83-100)。
- 前7例接受较低剂量全身照射(200 vs 400 cGy)的患者移植物失败更常见(7例中3例 vs 较高剂量组20例中0例,P=.01,Fisher精确检验)。
- 采用400 cGy全身照射的HLA单倍体相合骨髓移植联合移植后环磷酰胺方案在20例连续患者中实现100%总生存且移植物抗宿主病发生率低。
关键数值与推荐
- 第100天2级或4级急性移植物抗宿主病累积发生率为7%(95%CI,不适用-17)。
- 2年慢性移植物抗宿主病累积发生率为4%(95%CI,不适用-11)。
- 27例患者1、2、3年总生存率均为92%(95%CI,83-100)。
- 前7例接受较低剂量全身照射(200 vs 400 cGy)的患者移植物失败更常见(7例中3例 vs 较高剂量组20例中0例,P=.01,Fisher精确检验)。
临床怎么用
- 作者认为,该方案避免了免疫抑制治疗的不良后果及其较低的无失败生存率,且使用单倍体相合供者扩大了所有人群中骨髓移植的可及性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Severe aplastic anemia (SAA) is a marrow failure disorder with high morbidity and mortality. It is treated with bone marrow transplantation (BMT) for those with fully matched donors, or immunosuppressive therapy (IST) for those who lack such a donor, which is often the case for underrepresented minorities. We conducted a prospective phase 2 trial of reduced-intensity conditioning HLA-haploidentical BMT and posttransplantation cyclophosphamide (PTCy)-based graft-versus-host (GVHD) prophylaxis as initial therapy for patients with SAA. The median patient age was 25 years (range, 3-63 years), and the median follow-up time was 40.9 months (95% confidence interval [CI], 29.4-55.7). More than 35% of enrollment was from underrepresented racial/ethnic groups. The cumulative incidence of grade 2 or 4 acute GVHD on day 100 was 7% (95% CI, not applicable [NA]-17), and chronic GVHD at 2 years was 4% (95% CI, NA-11). The overall survival of 27 patients was 92% (95% CI, 83-100) at 1, 2, and 3 years. The first 7 patients received lower dose total body irradiation (200 vs 400 cGy), but these patients were more likely to have graft failure (3 of 7) compared with 0 of 20 patients in the higher dose group (P = .01; Fisher exact test). HLA-haploidentical BMT with PTCy using 400 cGy total body irradiation resulted in 100% overall survival with minimal GVHD in 20 consecutive patients. Not only does this approach avoid any adverse ramifications of IST and its low failure-free survival, but the use of haploidentical donors also expands access to BMT across all populations. This trial was registered at www.clinicaltrials.gov as NCT02833805.
引用
- DeZern AE, Zahurak M, Symons HJ, et al. Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemia. Blood. 2023. PMID: 37084383. doi:10.1182/blood.2023020435
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。